Patent Application
20140249524
The present disclosure pertains to medical devices and methods for making and using medical devices. More particularly, the present disclosure pertains to medical devices and methods for performing renal nerve modulation.
Certain treatments require the temporary or permanent interruption or modification of select nerve function. One example treatment is renal nerve ablation, which is sometimes used to treat conditions related to congestive heart failure or hypertension. The kidneys produce a sympathetic response to congestive heart failure, which, among other effects, increases the undesired retention of water and/or sodium. Ablating some of the nerves running to the kidneys may reduce or eliminate this sympathetic function, which may provide a corresponding reduction in the associated undesired symptoms.
Many nerves, including renal nerves, run along the walls of or in close proximity to blood vessels and thus can be accessed via the blood vessels. In some instances, it may be desirable to ablate perivascular renal nerves using radiofrequency energy. The target nerves must be heated sufficiently to make them nonfunctional; however tissue adjacent to the nerves may also be damaged. It may be desirable to provide for alternative systems and methods for intravascular nerve modulation that reduce damage to surrounding tissues.
The disclosure is directed to several alternative designs, materials and methods of manufacturing medical device structures and assemblies for performing nerve ablation and method for performing nerve ablation.
Accordingly, one illustrative embodiment is a method for performing nerve modulation. A nerve modulation system including an electrode adjacent to a distal end of the nerve modulation system and a control unit may be provided. The nerve modulation system may be advanced through a lumen such that the electrode is adjacent to a target region. The electrode may be brought into contact with a wall of the lumen and power then applied to the electrode. A temperature adjacent to the electrode may be measured. The control unit may include a control algorithm for controlling a power level and a duration power is applied to the electrode.
Another illustrative embodiment is a nerve modulation system including an elongate shaft having a proximal end and a distal end. An electrode may be positioned adjacent to the distal end of the elongate shaft. The nerve modulation system may further include a control unit positioned adjacent to the proximal end of the elongate shaft. The control unit may include a control algorithm configured to control power applied to the electrode.
The above summary of some example embodiments is not intended to describe each disclosed embodiment or every implementation of the invention.
The invention may be more completely understood in consideration of the following detailed description of various embodiments in connection with the accompanying drawings, in which:
While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit aspects of the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.
For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.
All numeric values are herein assumed to be modified by the term “about”, whether or not explicitly indicated. The term “about” generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (i.e., having the same function or result). In many instances, the term “about” may be indicative as including numbers that are rounded to the nearest significant figure.
The recitation of numerical ranges by endpoints includes all numbers within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).
Although some suitable dimensions ranges and/or values pertaining to various components, features and/or specifications are disclosed, one of skill in the art, incited by the present disclosure, would understand desired dimensions, ranges and/or values may deviate from those expressly disclosed.
As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.
For purposes of this disclosure, “proximal” refers to the end closer to the device operator during use, and “distal” refers to the end farther from the device operator during use.
The following detailed description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The detailed description and the drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention. The illustrative embodiments depicted are intended only as exemplary. Selected features of any illustrative embodiment may be incorporated into an additional embodiment unless clearly stated to the contrary.
Certain treatments require the temporary or permanent interruption or modification of select nerve function. One example treatment is renal nerve ablation, which is sometimes used to treat conditions related to congestive heart failure or hypertension. The kidneys produce a sympathetic response to congestive heart failure, which, among other effects, may increase the undesired retention of water and/or sodium. Ablating some of the nerves running to the kidneys may reduce or eliminate this sympathetic function, which may provide a corresponding reduction in the associated undesired symptoms.
While the devices and methods described herein are discussed relative to renal nerve modulation, it is contemplated that the devices and methods may be used in other locations and/or applications where nerve modulation and/or other tissue modulation including, but not limited to, heating, activation, blocking, disrupting, or ablation are desired, such as, but not limited to: blood vessels, urinary vessels, or in other tissues via trocar and cannula access. For example, the devices and methods described herein can be applied to hyperplastic tissue ablation, tumor ablation, benign prostatic hyperplasia therapy, nerve excitation or blocking or ablation, modulation of muscle activity, hyperthermia or other warming of tissues, etc. In some instances, it may be desirable to ablate perivascular renal nerves with radiofrequency (RF) energy. The term modulation refers to ablation and other techniques that may alter the function of nerves and other tissue such as brain tissue or cardiac tissue. When multiple ablations are desirable, they may be performed sequentially by a single ablation device.
Mammalian anatomy can vary greatly from one specimen to another. Internal studies of human renal anatomy have shown that most nerves (approximately 90%) tend to be within 2 millimeters (mm) of the inner surface of the artery wall. Therefore, it may be desirable to perform renal nerve modulation to a minimum depth of 2 mm. However, as some nerves may be further than 2 mm from the artery wall, it may be desirable to perform nerve modulation to a depth deeper than 2 mm. As the depth of the desired treatment region is expanded, the risk of damaging adjacent structures, such as, but not limited to, the bowel or psoas muscle, increases. Damage to tissue outside of the desired treatment region may cause additional pain for the patient or other medical issues depending on the severity of the damage. Therefore, it may be desirable to limit the depth of the treatment region. For example, it may be desirable to limit the depth of the treatment region to approximately less than 4 mm from the vessel wall.
In order to alter the function of the nerves or other tissue, it may be desirable to heat the target region to a point where the tissue begins to denature or irreversibly change, for example, to approximately 50-65° C. It may be desirable to maintain the temperature of the tissue surrounding the modulation system less than 90° C. (e.g., less than 65° C.) so as to minimize any undesired impact on these tissues. Controlling the electrode temperature below 65° C. may reduce the coagulation of blood on the electrode and artery surface and prevent the blood and/or artery surface from turning brown or black. At temperatures greater than 100° C., the water in the tissue may begin to boil creating steam and causing injury. It is contemplated that the target region may be heated to a minimum of 50° C., the temperature at which the function of the nerves may be altered. It is contemplated that heating the target region (a depth of 4 mm) to the desired temperature range (50-65° C.) in as short of a time as possible may limit the spread of heat beyond the target region due to conduction which can cause undesirable injury to the adjacent structures as well as prevent steam formation.
A variety of different ablation devices may be used to modulate and/or ablate nerve tissue adjacent to a renal artery. While these devices may be configured to ablate tissue across a broad range of depths within a given treatment region and/or raise the temperature of the target tissue any number of degrees, these devices are generally not specifically designed to target nerve tissue while simultaneously minimizing damage to surrounding tissue. For example, a number of ablation devices may be configured to ablate tissue at locations relatively near to a renal artery vessel wall, at locations relatively far from the renal artery vessel wall, and locations in between. However, these devices are not specifically tuned to a particular target depth so that only targeted renal nerves are ablated. Thus, some devices designed to treat across a broad range of tissue depths and/or designed to simply raise the temperature any number of degrees could undesirably effect (e.g., cause damage to) surrounding tissue.
Furthermore, part of targeting nerves at a particular depth or distance away from the vessel wall may include raising the temperature to a particular temperature range at the target location/depth while minimizing the temperature changes at surrounding areas. Therefore, not only is a specific target depth a potentially important factor to consider when performing an intervention (e.g., a renal nerve ablation procedure), the ability to raise the temperature at that depth while reducing temperature changes at surrounding areas may be desirable.
Disclosed herein are devices/systems and method that are designed to aid in a variety of medical interventions including renal nerve ablation procedures. The example devices disclosed herein may be configured to target tissue (e.g., renal nerves) located within a particular range of depths or distances away from the vessel wall of a renal artery. In addition, the example devices may be configured to increase the temperature at the target tissue (e.g., adjacent to the renal nerves) so that potential damage to surrounding tissue can be reduced. A number of structural features of these devices including, for example, deflectability and/or controlled contact force with the vessel, size of the ablation electrode, and the like may also contribute to the ability of these devices to achieve the desired end result. Furthermore, the example methods disclosed herein may be designed to achieve ablation at the desired depth while achieving the desired temperature change. This may include the use of a number of methods, protocols, and/or algorithms that precisely control the power delivered to the ablation device (e.g., ablation electrode), the depth to which ablation occurs, the temperature changes of target and surrounding tissue, the contact force of the ablation member/electrode with the vessel wall, and other factors so as to achieve controlled ablation. Some details regarding these devices and methods are disclosed in more detail herein.
The system 100 may include a distal ablation electrode 110 positioned adjacent the distal end region 108 of the elongate shaft. While the ablation electrode 110 is described as a radiofrequency electrode, it is contemplated that other methods and devices for raising the temperature of the nerves may be used, such as, but not limited to: ultrasound, microwave, or other acoustic, optical, electrical current, direct contact heating, or other heating. While the system 100 is illustrated as including one ablation electrode 110, it is contemplated that the modulation system 100 may include any number of ablation electrodes 110 desired, such as, but not limited to, two, three, four, or more. If multiple ablation electrodes 110 are provided, the ablation electrodes 110 may be longitudinally and/or radially and/or circumferentially spaced as desired. In some embodiments, the ablation electrode 110 may include a cylindrical electrode with a hemispherical end adjacent the distal end of the elongate shaft 106. In other instances, the electrode 110 may include wire wrapped coils, generally solid shapes, ball-type electrodes, etc. In some embodiments, the ablation electrode 110 may be formed of a separate structure and attached to the elongate shaft 106. For example, the ablation electrode 110 may be machined or stamped from a monolithic piece of material and subsequently bonded or otherwise attached to the elongate shaft 106. In other embodiments, the ablation electrode 110 may be formed directly on the surface of the elongate shaft 106. For example, the ablation electrode 110 may be plated, printed, or otherwise deposited on the surface. It is contemplated that the ablation electrode 110 may take any shape desired, such as, but not limited to, square, rectangular, circular, elliptical, etc. In some instances, the ablation electrode 110 may be a radiopaque marker band. The ablation electrode 110 may be formed from any suitable material such as, but not limited to, platinum, gold, stainless steel, cobalt alloys, or other non-oxidizing materials. In some instances, titanium, tantalum, or tungsten may be used.
In some embodiments, the ablation electrode 110 may have rounded edges in order to reduce the effects of sharp edges on current density. The size of the ablation electrode 110 may be chosen to optimize the current density without increasing the profile of the modulation system 100. For example, an ablation electrode 110 that is too small may generate high local current densities resulting in higher tissue temperatures with reduced cooling from the blood. An ablation electrode 110 that is too large may require larger, undesirable vascular access devices or be difficult to accurately manipulate and place the tip at the target tissue. In some embodiments, the electrode may have a length L of approximately 0.167 inches (or approximately 4.25 mm) and a width or diameter D of approximately 0.050 inches (or approximately 1.27 mm). It is contemplated that the width of the electrode may be selected to be compatible with a 6 French guide catheter. These are just examples. In some instances, only a portion of the electrode length may be exposed during the ablation procedure. For example, less than 90%, less than 75%, less than 50%, or less than 25% of the total electrode length may be exposed. These ranges are merely exemplary. It is contemplated that any desired length of the electrode may be exposed. In some instances, a longer electrode may further reduce the maximum electrode and tissue temperature for improved safety from blood coagulation, vessel lumen tissue burn, thrombus, and tissue steam pops. It is further contemplated that a longer electrode may run cooler than a shorter electrode due to increased contact area between the electrode and the blood and a more disuse electrical field. In some instances, the ablation electrode 110 may have an aspect ratio of 1.8:1 (length to width) or greater although this is not required. It is completed that the aspect ratio of the ablation electrode 110 may be in the rage of 1:1 to 2.5:1 (length to width) Such an elongated structure may provide the ablation electrode 110 with more surface area without increasing the profile of the modulation system 100. It is contemplated that the ablation electrode 110 may also be sized according to the desired treatment region. For example, in renal applications, the ablation electrode 110 may be sized to be compatible with a 6 French guide catheter, although this is not required.
While not explicitly shown, the ablation electrode 110 may also include other structures and/or features associated typically associated with ablation (e.g., thermal ablation) such as a temperature monitoring member, which may take the form of a thermocouple or thermistor. In at least some embodiments, a thermistor including two thermistor wires may be disposed adjacent to ablation electrode 110. In some embodiments, the wires are not physically connected to ablation electrode 110. The thermistor wires may terminate in a center bore of the ablation electrode 110 and may be potted with a thermally conducting epoxy in a plastic tube which is then glued to the bore of the ablation electrode 110.
The modulation system 100 may be advanced through the vasculature in any manner known in the art. For example, system 100 may include a guidewire lumen to allow the system 100 to be advanced over a previously located guidewire. In some embodiments, the modulation system 100 may be advanced, or partially advanced, within a guide catheter such as the guide catheter 16 shown in
In some instances, multiple treatments may be used to achieve the desired tissue modulation. In some instances, the elongate shaft 106 may be rotated and additional ablation can be performed at multiple locations around the circumference of the vessel 102. The number of times the elongate shaft 106 is rotated at a given longitudinal location may be determined by the number and size of the ablation electrodes 110 on the elongate shaft 106. Once a particular location has been ablated, it may be desirable to perform further ablation procedures at different longitudinal locations. If necessary, the elongate shaft 106 may be rotated to perform ablation around the circumference of the vessel 102 at each longitudinal location. This process may be repeated at any number of longitudinal locations desired. In some instances, the treatment may be performed in a helical pattern such that each treatment region is longitudinally and radially spaced from the adjacent treatment region.
During an ablation procedure when the electrode 110 contacts tissue and energy is supplied to the electrode 110, the tissue begins heat. As ablation continues, the electrode 110 also may begin to heat. If the contact between the vessel wall 104 and the electrode 110 is not sufficient, blood may pass over the surface of the electrode 110 thus cooling the electrode 110. The temperature at and/or adjacent to the electrode 110 may be measured and the measurement may be used to help determine if there is sufficient contact between the electrode 110 and the vessel wall 104. For example, a thermistor may be used to monitor the temperature at the electrode. If the temperature is below a predetermined threshold at a predetermined time point at a predetermined power, an error code or message may be generated by or at the control unit (such as control unit 18, shown in
It is further contemplated that the tip contact between the electrode 110 and the vessel wall 104 may be monitored using a low power to monitor small increases in the temperature of the electrode 110. For example, before the ablation procedure is performed, power may be supplied to the electrode 110 at a power less than the treatment power. If the temperature at or adjacent to the electrode 110 does not increase at least 1° C. within 5 seconds, the control unit 18 may determine the tip is not heating and alert the user. For example, in some instances, the user may receive a message indicating the electrode needs to be repositioned.
In some embodiments, the distal end region 108 may be deflected such that the electrode tip 118 exerts a force on the inner surface of the vessel wall 104. Exerting a force against the vessel wall 104 may improve the stability of the modulation system 100 during the ablation procedure and the contact between the vessel wall 104 and the electrode 110. For example, positioning the electrode tip 118 against a first side 114 of the vessel wall 104 and an intermediate region 112 of the elongate shaft 106 against a second side 116 of the vessel wall 104 may help prevent the elongate shaft 106 from moving during the procedure. For example, the opposite outward forces of the electrode tip 118 and the intermediate region 112 on the inner surface of the vessel wall 104 may act as a gripping mechanism. It is further contemplated that deflecting the distal end region 108 such that the electrode tip 118 exerts a force on the vessel wall may achieve better and/or more consistent electrode 110 to vessel wall 104 contact. In some instances it may be desirable for the operator to apply a tip force in the range of 5 to 30 grams (g).
The force with which the electrode tip 118 contacts the vessel wall 104 may affect the starting impedance. The impedance of the vessel wall 104 may be greater than the impedance of the blood, or surrounding fluid. For example, the vessel wall 104 and/or surrounding tissue may have an impedance of approximately 300-400 ohms (Ω) while blood may have an impedance in the range of approximately 150-180Ω. It is contemplated that the starting impedance may be approximated based on the percentage of the electrode 110 which contacts the vessel wall 104. For example, the measured impedance may increase with increasing tissue contact. Thus, the greater the contact force (and thus the greater the surface area of the electrode 110 contacting the wall 104) the higher the starting impedance may be as more current travels through the higher impedance tissue from the electrode 110. Therefore, the starting impedance may be used to determine an approximate tip force. It is contemplated that it may be desirable for the starting impedance to be at least 40Ω above the impedance of the blood and at least 100Ω below the impedance of the surrounding tissue.
The amount of change of the impedance may depend on the frequency at which the impedance is measured. For example, when the impedance is measured at a lower frequency, such as, but not limited to, 46 KHz, the change in impedance with increasing tip force may be larger than the change in impedance measured at a higher frequency, such as, but not limited to 460 KHz. Measuring the impedance at a lower frequency may provide a more sensitive reading, thus allowing the operator greater control over the force with which the electrode tip 118 contacts the vessel wall 104.
A low tip force in which the electrode tip 118 has minimal contact with the vessel wall 104 (or other tissue) may have starting impedance similar to the impedance of the blood flowing through the vessel. It is contemplated that the due to the minimal tip contact with the tissue, the maximum ablation temperature of the target region may be low, for example, less than 50° C. A medium tip force, in which, for example, approximately 25% of the electrode tip 118 area contacts the vessel wall 104 (or other tissue), may have a starting impedance in the range of 200-225Ω. However, this range is merely exemplary and may vary based on the impedance of the tissue and/or blood. It is contemplated that the maximum ablation temperature of the target region may be between 50° C. and 60° C. when a medium tip force is utilized. A high tip force, in which, for example, approximately 50% of the electrode tip 118 area contacts the vessel wall 104 (or other tissue), may have a starting impedance in the range of 250-265Ω However, this range is merely exemplary and may vary based on the impedance of the tissue and/or blood. It is contemplated that the maximum ablation temperature of the target region may be limited by a control algorithm when a high tip force is used. For example, a control algorithm may be configured to limit the maximum temperature at or adjacent to the electrode tip 118 to less than 65° C., although this is not required. It is contemplated that the maximum temperature may be selected based on the desired treatment.
It is contemplated that the surface area of the electrode 110 that contacts the vessel wall 104 may impact how quickly or to what degree the surrounding tissue is heated. When the electrode tip 118 does not contact the vessel wall 104 or minimally contacts the wall, a small fraction of the current may flow from the electrode 110 through the vessel wall 104 and to the desired treatment region. Therefore, the desired treatment region may not reach the target temperature required to perform tissue modulation. When a large fraction of the electrode tip 118 contacts the vessel wall 104, a large fraction of the current may pass from the electrode 110 through the vessel wall 104 and to the desired treatment region. In this situation, the temperature of the target region may become too hot or tissues outside of the desired target region may be damaged as the heat penetrates deeper than the desired target region. Therefore, it may be desirable to control the force with which the electrode tip 118 contacts the vessel wall 104, and thus the amount of surface area of the electrode 110 contacting the vessel wall 104. Because there is anatomy variability it may be desirable to give the operator a range of tip force to ensure adequate tip contact while limiting the maximum tip force and tip power to minimize excessive heating and undesirable tissue injury. For example, it is contemplated the tip force with which the electrode tip 118 contact the vessel wall 104 may range from approximately 5 to 30 grams
While not explicitly shown, the ablation electrode 110 may be connected to a control unit or to separate control units (such as control unit 18 in
In some instances, the control unit 18 may include alternative control algorithms for different operating conditions. For example, if the electrode tip 118 is overheating, for example, if the electrode tip 118 has a temperature greater than 65° C., the control unit 18 may operate using an alternative algorithm 204. In some instances, when a temperature greater than 65° C. is measured, the control unit 18 may decrease the power supplied to the electrode 110 as shown in curve 204 in
In some embodiments, the control unit 18 may be further configured to stop ablation if an upper temperature limit is reached. For example, the control unit 18 may be configured to stop ablation if a temperature of 75° C. is reached at the electrode tip 118. In some embodiments, the control unit 18 may be configured to provide a visual or audio alarm, such as an error code or message, to alert the user that the electrode tip 118 is not heating. For example, if the electrode tip 118 has not reach a predetermined temperature, such as, but not limited to, 43° C., by a predetermined time, such as, but not limited to, 5 seconds, the user may be alerted that the tip 118 is not heating and the contact between the electrode tip 118 and the vessel wall 104 is not sufficient. The user may then stop the ablation procedure, if the control unit 18 has not done so automatically, and reposition the electrode tip 118. As noted above, the starting impedance may be measured and used a guideline for determining the approximate tip 118 contact area and/or force with which the electrode tip 118 contacts the vessel wall 104. In some instances, a higher electrode tip 118 to vessel wall 104 contact force may increase the probability of achieving adequate tip contact and energy delivery without generating alarms.
In some instances, the electrode tip 118 may shift during the modulation procedure. The control unit 18 may monitor the temperature at or adjacent to the electrode 110 to determine if the electrode tip 118 has lost contact with the vessel wall 104. For example, if the temperature drops 7° C. or more (or other predetermined amount) for more than 5 seconds (or other predetermined threshold), the ablation procedure may be stopped. A time frame of approximately 10 seconds or time averaging may help reduce faults that may be triggered by brief losses of contact due to respiration, heart beats, or other reasons.
It is contemplated that the duration of the procedure may be determined by the desired procedure. For example, in some instances, the treatment may continue until a desired temperature reaches a desired depth. In some embodiments, the treatment may continue until a desired treatment region reaches 50° C.
The effect of tip force and length of time of the treatment was studied on bench tissue. Swine myocardial tissue was placed in a 37° C. salt solution. Power was applied to the electrode at 8 Watts with a temperature limit of 70° C. The maximum depth of the lesion was measured for two procedure times, 30 seconds and 120 seconds for a high tip force having an impedance of approximately 260 ohms and approximately greater than 50% area contact, a medium tip force having an impedance of approximately 220 ohms and approximately 25% area contact, and a low tip force having an impedance of approximately 190 ohms. As noted above, the amount of surface area of electrode contacting the vessel wall and/or treatment area is proportional to the tip force. As such, impedance may be used to determine the approximate surface area contacting the treatment region and thus the approximate tip force.
The effect of time and power on lesion depth and lesion volume was studied on two separate devices. The results are summarized in graph 500 (lesion depth) shown in
In a first test, Device 1 was used to perform tissue modulation on swine myocardial tissue. Energy was supplied to the electrode at 8 W for 120 seconds. As shown at bar 502 in
Overall, the experiments illustrate that reducing the time of the procedure or reducing the power decreases the lesion depth and volume. Reducing the tip force can also reduce the lesion depth. As can be seen, the fourth test (Device 2, 8 W, 30 seconds) appears to provide a lesion that is deep enough to ablate to the minimum depth of 2 mm but not so deep as to cause undesirable damage to surrounding tissues. The fourth test also minimizes the duration of the test procedure (as compared to the seventh test) which may help reduce side effects from an extended procedure. For example, a shorter procedure duration may help reduce the duration of pain experienced by patients during treatment, the overall procedure time, errors due to loss of contact and may reduce the maximum temperature of the tissue immediately adjacent to the electrode.
Renal tissue norepinephrine levels may provide an indication of the efficacy of the renal nerve ablation procedure. For example, a decrease in mean kidney norepinephrine may indicate that the function of the nerves has been altered to impact the sympathetic function of the nerves. Swine renal arteries were treated using a helical pattern where treatment regions were spaced by 5 mm and 90 degrees. The number of treatments were determined by the artery length and ranged from four to eight treatments per artery. The animals were treated with device 1 with a maximum power of 8 Watts over 120 seconds. The animals were treated with device 2 with a maximum power of 8 Watts over 30 seconds. Both devices were operated at 460 KHz and a temperature limit of 70° C.
The mean kidney norepinephrine levels were measured 7 days after treatment. The results are summarized in Graph 700 illustrated in
As can be seen at bar 704, Device 1, operated for 120 seconds at 8 W, had an approximately 61% reduction in norepinephrine relative to the Sham group. Device 2, operated for 30 seconds at 8 W, had an approximately 59% reduction in norepinephrine, as shown at bar 706. The two treatment groups were not significantly different from each other but both were significantly lower than the “Sham” group by students t-test, p<0.5. Treatment times less than 120 seconds may be efficacious, reduce procedure time, patient pain, and injury to structures like the psoas muscle, which can be close to the renal artery.
Those skilled in the art will recognize that the present invention may be manifested in a variety of forms other than the specific embodiments described and contemplated herein. Accordingly, departure in form and detail may be made without departing from the scope and spirit of the present invention as described in the appended claims.
This application claims priority under 35 U.S.C. §119 to U.S. Provisional Application Ser. No. 61/771,700, filed Mar. 1, 2013, the entirety of which is incorporated herein by reference.
| Number | Date | Country | |
|---|---|---|---|
| 61771700 | Mar 2013 | US |
